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Perspective from the Alzheimer’s Association: Neuroimaging
Professional Interest Area of ISTAART continues impact on the fieldMore than 5 million Americans [1] and 35 million people
worldwide are estimated to be living with Alzheimer’s dis-
ease (AD) today, with the prevalence expected to quadruple
by 2050 as the world’s population ages [2]. Although Dr.
Alois Alzheimer first described AD more than a century
ago [3,4], advances in therapy development have remained
elusive. Today’s current therapies provide symptomatic
relief, and there is no evidence that they stop or slow the
progression of the underlying disease process. The search
for disease-modifying therapies has been hampered by a
lack of knowledge about the course of the disease process.
Data from clinical, imaging, biomarker, genomic, and other
omic studies combined with electronic health records, payer
claims, and new technologies that track real-time data
should inform a better understanding of the earliest neuro-
pathological and behavioral events that herald the oncoming
disease.
The in vivo imaging biomarkers field for Alzheimer’s dis-
ease and related disorders is rapidly expanding, and neuroi-
maging has emerged as a critical research and diagnostic
tool in the field of AD and other dementias. In 2004, re-
searchers from the University of Pittsburgh, led by Drs. Wil-
liam Klunk and Chet Mathis, reported for the first time at the
Alzheimer’s Association International Conference (AAIC;
formerly the International Conference on Alzheimer’s Dis-
ease) on an imaging agent called Pittsburgh compound B
(PiB), a major potential breakthrough in disease monitoring
and early detection. PiB enters the brain through the blood-
stream and attaches itself to beta-amyloid deposits, where it
can be detected by positron emission tomography (PET).
This set the stage for the next decade of research on beta-
amyloid imaging ligands. The Alzheimer’s Association pro-
vided significant support to initiatives to develop PiB and
conduct preclinical testing in animal studies.
Also in 2004, the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) launched as a model of private and public
partnership to establish standards for obtaining and interpret-
ing brain images across the nation. In 2005, the Alzheimer’s
Association provided $2.4 million in funding for the ADNI
PiB add-on study which was pivotal in our understanding
about the accumulation of beta-amyloid in later life. Findings
resulting from ADNI have influenced the field in dramatichttp://dx.doi.org/10.1016/j.dadm.2016.10.004
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ways [5]. For example, ADNI data influenced Jack et al. to
develop one of the most widely accepted models of temporal
dynamics of biomarkers in the development and progression
of AD [6–8]. This hypothetical model creates a change in how
the global research enterprise considers the disease landscape,
supporting the deliberations that ultimately led to the
2011 revised National Institute on Aging–Alzheimer’s
Association (NIA-AA) guidelines for AD diagnosis [9–11],
as well as informing the design of large scale AD studies
that are currently testing methods that may delay or even
completely prevent the onset of dementia symptoms in
individuals whose biomarkers suggest they are in the pre-
symptomatic phase of the disease [12].
The Alzheimer’s Association created the International
Society to Advance Alzheimer’s Research & Treatment
(ISTAART) in 2008 to facilitate connection of researchers
across the globe around specific scientific topic areas.
Within ISTAART, affinity groups called Professional In-
terest Areas began, and one of the first focused on neuro-
imaging and continues to grow and expand engagement
of the scientific community. Consistently, the neuroimag-
ing PIA leadership of researchers has fostered a spirit of
collaboration and an emphasis on awards that recognize
junior investigators making exceptional advances in
neuroimaging-related research.
The neuroimaging PIA organizes the Alzheimer’s Imag-
ing Consortium (AIC) as a 1-day preconference for AAIC;
the AIC focuses on the clinical application and methodolog-
ical development of neuroimaging (MRI, PET, SPECT, CT,
and others) to AD, other dementias, and normal brain aging.
As an integral component of AAIC and a highly anticipated
annual meeting, the AIC brings together nearly 1000 re-
searchers from around theworld for the latest science as neu-
roimaging continues to advance our understanding of AD
and related dementia. Furthermore, the leadership of the
neuroimaging PIA advocated and aligned initiatives to pub-
lish this special volume of Alzheimer’s & Dementia: Diag-
nosis, Assessment & Disease Monitoring as a way to
capture and highlight the AIC advances.
In 2015, the neuroimaging PIA established an educa-
tional workshop to convene leading experts for this 1-day
multimodal program, with an emphasis to provideimer’s Association. This is an open access article under the CC BY-NC-ND
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engaging the larger research community in learnings sur-
rounding neuroimaging. The inaugural workshop in 2015
was a half day, and in 2016, this workshop became a 1-day
event focused on in-depth understanding and an update of
the fundamental principles, inherent limitations, and the
latest in clinical and research applications of the most
prominent neuroimaging modalities in the dementia field.
Together, the full day workshop trains diverse stakeholders
on the role of neuroimaging and the importance of the imag-
ing techniques to comprehensively probe the molecular,
cellular, and system-level neurodegenerative changes in
the brain [13].
Both, the AIC and the neuroimaging workshop at AAIC
as well as the emphasis on this special volume, are examples
of the strong leadership and impact of the Neuroimaging PIA
on the broader field; these activities provide vehicles that
further advance research discovery into the emerging area
of neuroimaging and its development as a critical research
and diagnostic tool in the field of Alzheimer’s disease and
other dementias. The Alzheimer’s Association recognizes
the tremendous volunteers who actively participate in the
ISTAART neuroimaging PIA, implementing important re-
sources for the field and making the PIA’s work a continued
reflection of the research community’s commitment to foster
enterprising discoveries and build on these findings for the
next advancements.Heather M. Snyder*
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